Approved indications
• Adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and maximally tolerated statin therapy, or when statins are not tolerated or insufficient, to reduce LDL cholesterol.
• Adults with established cardiovascular disease (such as prior heart attack, ischemic stroke, or symptomatic peripheral arterial disease) to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization, in addition to standard lipid-lowering therapy.

Off-label uses and evidence
• Clinicians may occasionally use PCSK9 inhibitors like Praluent for severe LDL elevations in complex or high-risk situations not strictly covered by the label (for example, statin-intolerant patients without established cardiovascular disease but with very high LDL), generally supported by extrapolation from trial data and guideline recommendations; this remains individualized and evidence is stronger for on-label populations than for purely off-label use.

Efficacy expectations
• LDL cholesterol reductions are typically large, often about 45% to 60% from baseline when added to statins, with effects seen within 4 weeks of starting therapy and maintained with ongoing dosing.
• In high-risk patients with established cardiovascular disease, Praluent has been shown to reduce the risk of major adverse cardiovascular events (such as heart attack and stroke) when added to standard therapy, with benefits emerging over months to a few years of continuous treatment.
• Compared with other PCSK9 inhibitors (such as evolocumab), Praluent provides a similar magnitude of LDL lowering and cardiovascular risk reduction; choice between them usually depends on cost, formulary coverage, injection schedule preference, and individual tolerability rather than clear differences in efficacy.

Typical dosing
• Adults with hyperlipidemia or established cardiovascular disease: common starting doses are 75 mg subcutaneously every 2 weeks or 300 mg subcutaneously every 4 weeks; the dose may be increased to 150 mg every 2 weeks if additional LDL lowering is needed.
• Doses are individualized based on baseline LDL cholesterol, treatment goals, and response, usually assessed with fasting or nonfasting lipid panels at regular intervals.

How to take the medicine
• Praluent is given as a subcutaneous injection, typically into the thigh, abdomen, or upper arm, rotating sites with each dose and avoiding tender, bruised, scarred, or damaged skin.
• It can be injected with or without regard to meals and at any time of day, as long as the timing between doses (every 2 weeks or every 4 weeks) is maintained.
• Patients or caregivers are often trained to self-inject using a prefilled pen or syringe; they should follow the product’s step-by-step instructions carefully each time.

Special dosing instructions
• If LDL cholesterol is much lower or higher than target, clinicians may adjust the dose (for example, continuing 75 mg every 2 weeks if LDL is at goal, or increasing to 150 mg every 2 weeks if the response is inadequate).
• When switching between 2-week and 4-week regimens, the total monthly dose and timing should be carefully coordinated with a healthcare professional.

Missed-dose guidance
• If a dose is missed and the next scheduled dose is more than 7 days away, the missed dose should generally be taken as soon as possible, then the regular schedule resumed.
• If a dose is missed and the next scheduled dose is within about 7 days, patients are usually advised to skip the missed dose and wait for the next scheduled injection, then continue the regular schedule; individual instructions from the prescriber or the product labeling should be followed.

Overdose
• There is limited experience with overdose of Praluent; taking more than prescribed could increase the risk of side effects without additional benefit.
• In case of suspected overdose, patients should contact their healthcare provider, local poison control center, or seek emergency medical care and bring the medication packaging or device with them.

Common side effects
• Common reactions include injection-site reactions (redness, pain, itching, swelling), mild flu-like symptoms, and nasopharyngitis or upper respiratory symptoms; these are usually mild to moderate and often appear within the first few injections.
• Some people report muscle pain, though this is generally less frequent and less severe than with statins; gastrointestinal symptoms such as nausea or diarrhea can also occur but are not very common.

Serious or rare adverse effects
• Serious allergic reactions (hypersensitivity), including reactions with rash, itching, swelling of the face or throat, trouble breathing, or severe dizziness, are rare but require immediate medical attention and discontinuation of the drug.
• Very rarely, more severe injection-site or systemic hypersensitivity reactions may occur; any signs of anaphylaxis or widespread rash should be treated as an emergency.

Warnings and precautions
• Pregnancy: there are limited data in pregnant women; because Praluent affects cholesterol pathways important for fetal development, it is usually avoided during pregnancy unless the potential benefit clearly outweighs the risk—patients should discuss pregnancy plans and contraception with their clinician.
• Breastfeeding: it is not known whether alirocumab passes into human milk in significant amounts; because it is a large protein that would be partly destroyed in the infant’s gut, risk may be low, but caution is advised and decisions should be individualized.
• Age limits: Praluent is approved for use in adults; safety and effectiveness have not been established in children or adolescents.
• Kidney or liver disease: no major dose adjustments are typically required in mild to moderate impairment, but patients with severe hepatic or renal dysfunction should be monitored carefully, and clinicians may adjust therapy based on overall risk and response.

Relative safety
• Overall, PCSK9 inhibitors like Praluent are generally well tolerated and have a favorable safety profile compared with many other lipid-lowering agents, with low rates of serious adverse effects in major clinical trials; long-term safety data continue to accumulate but have been reassuring so far.

Reporting side effects and safety updates
• Patients in the United States can report suspected side effects to FDA MedWatch (online, by phone, or by mail) and should also inform their prescriber and pharmacist.
• For the most current information on safety communications, patients and clinicians can consult FDA drug safety updates and the manufacturer’s prescribing information.

Drug and other interactions
• Praluent is a monoclonal antibody that is not metabolized through the liver enzymes (such as CYP450) that many pills use, so it has few traditional drug–drug interactions and is generally safe to use with statins, ezetimibe, and most blood pressure or diabetes medicines.
• No specific interactions are known with common OTC pain relievers, antihistamines, or acid-reducing drugs, but patients should always review all medications with their clinician.
• There are no well-documented interactions with foods or moderate alcohol intake, though overall cardiovascular health recommendations (such as limiting alcohol and eating a heart-healthy diet) still apply.

Precautions and conditions requiring caution
• History of serious hypersensitivity to alirocumab or to any component of the formulation is a contraindication; such patients should not receive Praluent again.
• Patients with severe liver disease, severe kidney disease, or complex cardiovascular histories should be monitored closely, and therapy tailored to their overall risk profile.
• Because long-term effects in pregnancy and childhood are not fully characterized, women who are pregnant or planning pregnancy, and parents of potential pediatric patients, should discuss the risks and benefits carefully with a specialist.

Monitoring needs
• Lipid panels (including LDL cholesterol) are typically checked 4 to 8 weeks after starting or adjusting Praluent, then periodically (for example, every 3 to 12 months) to ensure continued effectiveness and to guide dose adjustments.
• Routine monitoring of liver enzymes or muscle enzymes is generally driven more by concurrent statin use or other conditions than by Praluent itself, as the drug does not commonly cause liver or muscle injury.
• Clinicians will also monitor overall cardiovascular risk factors (blood pressure, diabetes control, smoking status, weight, and lifestyle) as part of ongoing care.

Q: How long does it take for Praluent to start lowering my cholesterol?
A: Praluent begins lowering LDL cholesterol after the first injection, and most people see the full effect within about 4 weeks, with levels staying low as long as injections are continued on schedule.

Q: Do I still need to take my statin if I am on Praluent?
A: In most cases, yes—Praluent is intended to be used in addition to maximally tolerated statin therapy, because the combination provides greater LDL reduction and cardiovascular protection than either alone, unless you cannot tolerate statins.

Q: Can I inject Praluent myself at home?
A: Many patients self-inject Praluent at home using a prefilled pen or syringe after being trained by a healthcare professional, following the instructions for injection sites, timing, and safe disposal of used devices.

Q: What happens if I miss a dose of Praluent?
A: If you miss a dose, what to do depends on how close you are to your next scheduled injection; in general, if there is more than about a week until the next dose you can inject the missed dose when you remember, but if it is close to the next dose you may be advised to skip it, so always follow the instructions in your medication guide or from your prescriber.

Q: Will I need to take Praluent for the rest of my life?
A: High cholesterol and cardiovascular risk are usually long-term conditions, so treatment with Praluent is often ongoing; your clinician will periodically reassess your LDL levels, overall risk, and any side effects to decide whether to continue, adjust, or stop therapy.

Storage
• Store Praluent pens or syringes in the refrigerator (36°F to 46°F / 2°C to 8°C) in the original carton, protected from light; do not freeze, and do not shake.
• If needed, it may usually be kept at room temperature (up to about 77°F / 25°C) in the original carton for a limited time (commonly up to 30 days); do not return it to the refrigerator once kept at room temperature—follow the product’s specific instructions on allowed room-temperature storage and discard after that time.

Preparation and use
• Let the pen or syringe warm to room temperature outside the refrigerator for about 30–45 minutes before injecting; do not use external heat sources such as microwaves or hot water.
• Inspect the solution: do not use if it is cloudy, discolored, or contains particles, or if the device appears damaged or has been frozen.

Disposal
• After injection, place used pens or syringes in an FDA-cleared sharps disposal container; do not throw loose needles or pens into household trash or recycling.
• When the sharps container is nearly full, follow local regulations or your pharmacy’s guidance for disposal; many communities, hospitals, or pharmacies have take-back programs for sharps.